Mindpeak, a leading provider of artificial intelligence (AI) for pathology, and Proscia®,
a leading provider of digital and computational pathology solutions,
have announced a partnership to broaden access to improved diagnosis for
cancer patients. Through the collaboration, the companies lay the
foundation for delivering tightly integrated AI-powered workflows that
enable pathologists to provide more efficient, informed, and
reproducible clinical decisions.
Up to 70% of clinical decisions depend on pathology.[1]
Laboratories are increasingly adopting digital pathology, which shifts
the standard of diagnosis from microscope to whole slide image, to meet
growing expectations for precision medicine. In doing so, they can
leverage AI to unlock new insights that empower pathologists in making a
diagnosis as well as drive efficiency and quality gains.
The newly announced partnership paves the way for delivering an
integrated solution that brings together Mindpeak’s CE-IVD algorithms
for immunohistochemistry (IHC) quantification* with Proscia’s CE-IVDR Concentriq® Dx**
software platform. Mindpeak’s AI solutions automatically detect and
measure the presence of biomarkers including HER2, Ki-67, and ER/PR for
breast cancer and PD-L1 for lung cancer. More algorithms will be
introduced soon. Their algorithm for detecting Ki-67 for breast cancer
has been proven to identify more patients eligible for treatment while
saving 80-90% in diagnostic time[2] and their HER2 algorithm just outperformed the competition[3] in HER2low scoring in accuracy and usability.
“Mindpeak is delivering fast and reliable tools to solve pathology’s
biggest challenges, and we are excited to expand their reach through
this partnership,” says Founder and CEO Felix Faber. “Leading
laboratories rely on Proscia’s Concentriq Dx because it offers the
robust functionality needed to achieve fully digital diagnosis and is
designed to seamlessly incorporate state-of-the-art AI into day-to-day
operations. Our integrated solution will enable us to assist a larger
number of pathologists and improve outcomes for even more patients.”
Concentriq Dx is a modern digital pathology platform that drives
primary diagnostic workflows for reference laboratories, hospitals, and
health systems of all sizes. It offers a compelling user experience that
allows pathologists to quickly transition away from the microscope and
work with speed and ease. An open platform, Concentriq Dx is designed to
integrate AI applications from Proscia, Proscia’s customers, and
leading third parties, including Mindpeak, into routine workflows so
that laboratories can realize the full promise of pathology’s
computational future at scale.
“Proscia has pioneered an open approach to digital pathology because
we believe it is the only way that laboratories can drive a complete
transformation of their practice,” says Stephan Fromme, Proscia’s Head
of Strategic Alliances. “Mindpeak’s IHC quantification algorithms are
already helping pathologists to make faster, more informed decisions in
clinical routine in the USA and EU to advance the quest for precision
medicine. We are looking forward to incorporating them into our
ecosystem through this partnership.”
*In the EU, Mindpeak’s CE-marked AI algorithms are fully compliant to
IVDR for clinical routine. In the USA, they are for research use only,
not for use in diagnostic procedures.
**Concentriq Dx is CE-marked under IVDR.
About Mindpeak
Mindpeak is Europe’s Leader for AI-software for pathology. Over
17,000 patients have been diagnosed with the help of Mindpeak’s AI. With
a focus on tissue biomarker analysis and discovery, Mindpeak serves
clinical labs and biopharma companies around the globe. Mindpeak’s
algorithms were the first AI in digital pathology to be used in routine
clinical diagnostics in the USA and EU.
About Proscia
Proscia is a software company that is accelerating pathology’s
digital transformation to change the way we understand diseases like
cancer. Its Concentriq digital pathology platform and powerful AI
applications are advancing the 150-year-old standard of research and
diagnosis towards a data-driven discipline, unlocking new insights that
accelerate R&D, improve patient outcomes, and fulfill the promise of
precision care. Leading diagnostic laboratories and 14 of the top 20
pharmaceutical companies rely on Proscia’s software each day. For more
information, visit proscia.com.
[1] NHS England (2017). Digital First: Clinical Transformation Through Pathology Innovation. National Pathology Programme; doi: https://www.england.nhs.uk/wp-content/uploads/2014/02/pathol-dig-first.pdf
[2]
Colón, E. et al. (2023) AI in combination with the global counting
methodology by the International Ki67 in Breast Cancer Working Group
identifies more patients eligible for treatment and increases diagnostic
speed by 5x-8x. Presented at USCAP 20s23. https://bit.ly/43ohY3u
[3] Mindpeak comes out on Top in a comparative Study on HER2low scoring by Cypath and Institut Gustave Roussy. https://lnkd.in/eYuY6R3m